Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Oct, 2014 | Pages:
141 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Metastatic Adenocarcinoma of The Pancreas - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Metastatic Adenocarcinoma of The Pancreas - Pipeline Review, H2 2014', provides an overview of the Metastatic Adenocarcinoma of The Pancreas's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Metastatic Adenocarcinoma of The Pancreas, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Adenocarcinoma of The Pancreas and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Metastatic Adenocarcinoma of The Pancreas - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Metastatic Adenocarcinoma of The Pancreas and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Metastatic Adenocarcinoma of The Pancreas products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Metastatic Adenocarcinoma of The Pancreas pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Metastatic Adenocarcinoma of The Pancreas - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Metastatic Adenocarcinoma of The Pancreas pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Metastatic Adenocarcinoma of The Pancreas Overview 8 Therapeutics Development 9 Pipeline Products for Metastatic Adenocarcinoma of The Pancreas - Overview 9 Pipeline Products for Metastatic Adenocarcinoma of The Pancreas - Comparative Analysis 10 Metastatic Adenocarcinoma of The Pancreas - Therapeutics under Development by Companies 11 Metastatic Adenocarcinoma of The Pancreas - Therapeutics under Investigation by Universities/Institutes 13 Metastatic Adenocarcinoma of The Pancreas - Pipeline Products Glance 14 Late Stage Products 14 Clinical Stage Products 15 Metastatic Adenocarcinoma of The Pancreas - Products under Development by Companies 16 Metastatic Adenocarcinoma of The Pancreas - Products under Investigation by Universities/Institutes 18 Metastatic Adenocarcinoma of The Pancreas - Companies Involved in Therapeutics Development 19 Aduro BioTech, Inc. 19 Axcentua Pharmaceuticals AB 20 BioCancell Therapeutics, Inc. 21 Boehringer Ingelheim GmbH 22 Boston Biomedical, Inc. 23 Eleison Pharmaceuticals, Inc. 24 Gilead Sciences, Inc. 25 Halozyme Therapeutics, Inc. 26 Incyte Corporation 27 Millennium Pharmaceuticals, Inc. 28 Nanotherapeutics, Inc. 29 NewLink Genetics Corporation 30 Novartis AG 31 Oncolytics Biotech Inc. 32 Sanofi 33 Teva Pharmaceutical Industries Limited 34 Threshold Pharmaceuticals, Inc. 35 Metastatic Adenocarcinoma of The Pancreas - Therapeutics Assessment 36 Assessment by Monotherapy Products 36 Assessment by Target 37 Assessment by Mechanism of Action 39 Assessment by Route of Administration 41 Assessment by Molecule Type 43 Drug Profiles 45 AXP-10711 - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 BBI-608 - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 BC-819 - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 BI-853520 - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 binimetinib - Drug Profile 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 CEP-37250 - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 CRS-207 - Drug Profile 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 Dendritic Cell Therapy for Cancer - Drug Profile 61 Product Description 61 Mechanism of Action 61 R&D Progress 61 erismodegib - Drug Profile 62 Product Description 62 Mechanism of Action 62 R&D Progress 62 evofosfamide - Drug Profile 65 Product Description 65 Mechanism of Action 65 R&D Progress 65 glufosfamide - Drug Profile 72 Product Description 72 Mechanism of Action 72 R&D Progress 72 indoximod - Drug Profile 74 Product Description 74 Mechanism of Action 74 R&D Progress 74 LGK-974 - Drug Profile 76 Product Description 76 Mechanism of Action 76 R&D Progress 76 MesoCART - Drug Profile 77 Product Description 77 Mechanism of Action 77 R&D Progress 77 MLN-0264 - Drug Profile 78 Product Description 78 Mechanism of Action 78 R&D Progress 78 paclitaxel lipsomal - Drug Profile 79 Product Description 79 Mechanism of Action 79 R&D Progress 79 PEGPH-20 - Drug Profile 81 Product Description 81 Mechanism of Action 81 R&D Progress 81 pelareorep - Drug Profile 82 Product Description 82 Mechanism of Action 82 R&D Progress 82 plerixafor - Drug Profile 87 Product Description 87 Mechanism of Action 87 R&D Progress 87 PRI-724 - Drug Profile 89 Product Description 89 Mechanism of Action 89 R&D Progress 89 ruxolitinib phosphate - Drug Profile 91 Product Description 91 Mechanism of Action 91 R&D Progress 91 siG-12D LODER - Drug Profile 95 Product Description 95 Mechanism of Action 95 R&D Progress 95 simtuzumab - Drug Profile 96 Product Description 96 Mechanism of Action 96 R&D Progress 96 Stem Cell Therapy for Oncology - Drug Profile 98 Product Description 98 Mechanism of Action 98 R&D Progress 98 Triapine - Drug Profile 99 Product Description 99 Mechanism of Action 99 R&D Progress 99 Metastatic Adenocarcinoma of The Pancreas - Recent Pipeline Updates 101 Metastatic Adenocarcinoma of The Pancreas - Dormant Projects 138 Metastatic Adenocarcinoma of The Pancreas - Discontinued Products 139 Appendix 140 Methodology 140 Coverage 140 Secondary Research 140 Primary Research 140 Expert Panel Validation 140 Contact Us 141 Disclaimer 141
List of Tables Number of Products under Development for Metastatic Adenocarcinoma of The Pancreas, H2 2014 9 Number of Products under Development for Metastatic Adenocarcinoma of The Pancreas - Comparative Analysis, H2 2014 10 Number of Products under Development by Companies, H2 2014 12 Number of Products under Investigation by Universities/Institutes, H2 2014 13 Comparative Analysis by Late Stage Development, H2 2014 14 Comparative Analysis by Clinical Stage Development, H2 2014 15 Products under Development by Companies, H2 2014 16 Products under Development by Companies, H2 2014 (Contd..1) 17 Products under Investigation by Universities/Institutes, H2 2014 18 Metastatic Adenocarcinoma of The Pancreas - Pipeline by Aduro BioTech, Inc., H2 2014 19 Metastatic Adenocarcinoma of The Pancreas - Pipeline by Axcentua Pharmaceuticals AB, H2 2014 20 Metastatic Adenocarcinoma of The Pancreas - Pipeline by BioCancell Therapeutics, Inc., H2 2014 21 Metastatic Adenocarcinoma of The Pancreas - Pipeline by Boehringer Ingelheim GmbH, H2 2014 22 Metastatic Adenocarcinoma of The Pancreas - Pipeline by Boston Biomedical, Inc., H2 2014 23 Metastatic Adenocarcinoma of The Pancreas - Pipeline by Eleison Pharmaceuticals, Inc., H2 2014 24 Metastatic Adenocarcinoma of The Pancreas - Pipeline by Gilead Sciences, Inc., H2 2014 25 Metastatic Adenocarcinoma of The Pancreas - Pipeline by Halozyme Therapeutics, Inc., H2 2014 26 Metastatic Adenocarcinoma of The Pancreas - Pipeline by Incyte Corporation, H2 2014 27 Metastatic Adenocarcinoma of The Pancreas - Pipeline by Millennium Pharmaceuticals, Inc., H2 2014 28 Metastatic Adenocarcinoma of The Pancreas - Pipeline by Nanotherapeutics, Inc., H2 2014 29 Metastatic Adenocarcinoma of The Pancreas - Pipeline by NewLink Genetics Corporation, H2 2014 30 Metastatic Adenocarcinoma of The Pancreas - Pipeline by Novartis AG, H2 2014 31 Metastatic Adenocarcinoma of The Pancreas - Pipeline by Oncolytics Biotech Inc., H2 2014 32 Metastatic Adenocarcinoma of The Pancreas - Pipeline by Sanofi, H2 2014 33 Metastatic Adenocarcinoma of The Pancreas - Pipeline by Teva Pharmaceutical Industries Limited, H2 2014 34 Metastatic Adenocarcinoma of The Pancreas - Pipeline by Threshold Pharmaceuticals, Inc., H2 2014 35 Assessment by Monotherapy Products, H2 2014 36 Number of Products by Stage and Target, H2 2014 38 Number of Products by Stage and Mechanism of Action, H2 2014 40 Number of Products by Stage and Route of Administration, H2 2014 42 Number of Products by Stage and Molecule Type, H2 2014 44 Metastatic Adenocarcinoma of The Pancreas Therapeutics - Recent Pipeline Updates, H2 2014 101 Metastatic Adenocarcinoma of The Pancreas - Dormant Projects, H2 2014 138 Metastatic Adenocarcinoma of The Pancreas - Discontinued Products, H2 2014 139
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
